JAMA Oncology

@jamaoncology.com

JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. 🌐 JAMAOncology.com

Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to more severe toxic effects, mainly infections, without survival benefit compared to atezolizumab alone. ja.ma/4wq74ZI

JAMA Oncology RCT for ES-SCLC. Study on 68 patients (25F, 43M) comparing Atezolizumab+TRT versus Atezolizumab only. Lungs icon & biohazard symbol. Atezolizumab only arm showed higher overall survival (13.4 vs 6.7 months). Combo arm recruitment terminated early due to adverse events. Survival curve graph shows divergent trends.

In a phase 1 trial of ultralow-dose IL-10–expressing CD19 CAR T cells for diffuse large B-cell lymphoma, 92% of adults had objective responses and most toxicities were grade 1-2, supporting further evaluation of cytokine-engineered CAR T strategies. ja.ma/4fk0oGA

Figure 2. Clinical Response to Interleukin 10-Expressing CD19 Chimeric Antigen Receptor T Cells. This bar chart shows individual patient responses over time (0-30 months) using stacked bars for disease status (Active, CR, PR, PD types) and symbols for retreatment, follow-up, or death.

Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to more severe toxic effects, mainly infections, without survival benefit compared to atezolizumab alone. ja.ma/4vjZWNb

JAMA Oncology study: Atezolizumab maintenance for ES-SCLC. 68 patients randomized. Kaplan-Meier plot shows Atezolizumab only arm (median OS 13.4 mo) had better survival than Atezolizumab+TRT arm (6.7 mo). Recruitment ended due to adverse events in TRT arm.

Among adults with lymphoma or myeloma, second primary malignant neoplasms after T-cell–engaging bispecific antibody therapy occurred in 3.5%, with most second primary malignant neoplasms being skin or hematologic cancers. ja.ma/3SlsYOG

Figure 2. Distribution of SPM Entities, a horizontal bar chart showing Total SPMs by Cancer type (y-axis) vs. SPM events (x-axis, 0-14). Nonmelanoma skin cancer has the highest SPM events (approx. 9), followed by MDS and Unknown (approx. 4 each).

Study of veterans with cancer identified high rates of suicidal self-directed violence, with greatest risk in younger, female, American Indian or Alaska Native, and those with central nervous system, pancreas, liver, thyroid, or head and neck cancer. ja.ma/3PAJSrL

Two line graphs show the estimated probability of Suicidal Self-Directed Violence (SSDV) over time for various cancer types, separated by stage. Both graphs indicate an increasing SSDV probability with time, with CNS, Pancreas, and Head/neck cancers showing consistently higher rates.